Jagdish C. Gupta
Research Subjects
Jagdish C. Gupta has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Gursaran Pran Talwar
Talwar Research Foundation, New Delhi, India
4 shared publications - Ambreen Rashid
Talwar Research Foundation, New Delhi, India
2 shared publications - Amulya Kumar Panda
Product Development Cell, National Institute of Immunology, New Delhi, India
2 shared publications - Anuja Krishnan
Department of Molecular Medicine, Jamia Hamdard, Delhi, India
2 shared publications - Kripa N. Nand
Department of Biological Sciences Rensselaer Polytechnic Institute Troy New York USA
2 shared publications - Arulandu Arockiasamy
Structural Biology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067. India
1 shared publication
Latest Publications
- 4 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (1) , 35
Survivin targeting triple-fusion vaccine DCSurvivin-LTB inhibits tumor growth in mouse model of triple-negative breast cancer
Survivin, an anti-apoptotic protein, plays a pivotal role in cancer progression by disrupting the balance between cell division and apoptosis. We have developed and characterized an anti-Survivin vaccine designed as a triple fusion protein to enhance immunogenicity. In this study, we have evaluated the vaccine’s efficacy in reducing tumor growth using a Survivin expressing 4T1 pre-clinical mouse model of triple-negative breast cancer (TNBC), which is difficult to treat due to its heterogeneous microenvironment, aggressive nature, poor prognosis, and high relapse rates. The recombinant DCSurvivin-LTB protein was purified, adsorbed onto alum, and formulated with Mycobacterium indicus pranii (MIP) before administration to Balb/c mice for dose optimization. The dose that maximized antibody production was selected for efficacy studies in 4T1 tumor-bearing mice in vivo. Vaccination elicited a strong anti-Survivin antibody response and significantly inhibited tumor growth compared with controls. Elevated Granzyme B levels in vaccinated mice indicated activation of the apoptotic pathway, contributing to tumor inhibition. IFN-γ, IL-2 and IL-12 levels were also higher after the vaccination which boosted the immune system to target the cancer cells. Histopathological analysis revealed no observable toxicity or adverse effects on major organs. Immunohistochemical analysis confirmed reduced expression of angiogenesis marker VEGF and increased expression of apoptotic marker Caspase 3. These findings highlight the potential of DCSurvivin-LTB, in combination with MIP, as a promising immunotherapeutic approach for the treatment of metastatic TNBC expressing Survivin.
- 4 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (1) , 35
Survivin targeting triple-fusion vaccine DCSurvivin-LTB inhibits tumor growth in mouse model of triple-negative breast cancer
Survivin, an anti-apoptotic protein, plays a pivotal role in cancer progression by disrupting the balance between cell division and apoptosis. We have developed and characterized an anti-Survivin vaccine designed as a triple fusion protein to enhance immunogenicity. In this study, we have evaluated the vaccine’s efficacy in reducing tumor growth using a Survivin expressing 4T1 pre-clinical mouse model of triple-negative breast cancer (TNBC), which is difficult to treat due to its heterogeneous microenvironment, aggressive nature, poor prognosis, and high relapse rates. The recombinant DCSurvivin-LTB protein was purified, adsorbed onto alum, and formulated with Mycobacterium indicus pranii (MIP) before administration to Balb/c mice for dose optimization. The dose that maximized antibody production was selected for efficacy studies in 4T1 tumor-bearing mice in vivo. Vaccination elicited a strong anti-Survivin antibody response and significantly inhibited tumor growth compared with controls. Elevated Granzyme B levels in vaccinated mice indicated activation of the apoptotic pathway, contributing to tumor inhibition. IFN-γ, IL-2 and IL-12 levels were also higher after the vaccination which boosted the immune system to target the cancer cells. Histopathological analysis revealed no observable toxicity or adverse effects on major organs. Immunohistochemical analysis confirmed reduced expression of angiogenesis marker VEGF and increased expression of apoptotic marker Caspase 3. These findings highlight the potential of DCSurvivin-LTB, in combination with MIP, as a promising immunotherapeutic approach for the treatment of metastatic TNBC expressing Survivin.
- 5 November 2024
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (2) , 281-294
Humanized recombinant immunotoxin targeting hCG demonstrates therapeutic potential for advanced stage difficult to treat cancers
We report the development of an immunotherapeutic molecule, a humanized immunotoxin, for treating hCG-expressing advanced-stage cancers. PiPP, a high-affinity anti-hCG monoclonal antibody, is used in the immunotoxin for 'homing' hCG-positive cancer cells. The deimmunized (DI) form of α-Sarcin, a fungal-origin toxin that lacks functional T-cell epitopes, is used in the design to ensure minimal immunogenicity of the immunotoxin for repetitive use in humans. A single-chain variable fragment (scFv) of PiPP was constructed by linking the humanized VH and VL regions of the antibody. The scFv part of the antibody was further linked to the toxin α-Sarcin (DI) at the gene level and expressed as a recombinant protein in E. coli. The immunotoxin was purified from the bacterial cell lysate and analyzed for binding and cytotoxicity to hCG-secreting colorectal and pancreatic cancer cells. The results showed that the scFv(PiPP)-Sarcin immunotoxin was able to bind to colorectal and pancreatic cancer cells and killed approximately 85% of the cells. In vivo testing of the immunotoxin produced results similar to those of in vitro testing against colorectal adenocarcinoma-induced tumors. This immunotoxin could be a promising immunotherapeutic agent for treating colorectal, pancreatic and other terminal-stage hCG-expressing cancers.
- 5 November 2024
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (2) , 281-294
Humanized recombinant immunotoxin targeting hCG demonstrates therapeutic potential for advanced stage difficult to treat cancers
We report the development of an immunotherapeutic molecule, a humanized immunotoxin, for treating hCG-expressing advanced-stage cancers. PiPP, a high-affinity anti-hCG monoclonal antibody, is used in the immunotoxin for 'homing' hCG-positive cancer cells. The deimmunized (DI) form of α-Sarcin, a fungal-origin toxin that lacks functional T-cell epitopes, is used in the design to ensure minimal immunogenicity of the immunotoxin for repetitive use in humans. A single-chain variable fragment (scFv) of PiPP was constructed by linking the humanized VH and VL regions of the antibody. The scFv part of the antibody was further linked to the toxin α-Sarcin (DI) at the gene level and expressed as a recombinant protein in E. coli. The immunotoxin was purified from the bacterial cell lysate and analyzed for binding and cytotoxicity to hCG-secreting colorectal and pancreatic cancer cells. The results showed that the scFv(PiPP)-Sarcin immunotoxin was able to bind to colorectal and pancreatic cancer cells and killed approximately 85% of the cells. In vivo testing of the immunotoxin produced results similar to those of in vitro testing against colorectal adenocarcinoma-induced tumors. This immunotoxin could be a promising immunotherapeutic agent for treating colorectal, pancreatic and other terminal-stage hCG-expressing cancers.
- 23 October 2024
- Published by Springer Nature in Systems Microbiology and Biomanufacturing
- Vol. 5 (1) , 171-184
Overexpression and characterization of recombinant hCGβ-LTB vaccine in fed-batch culture of yeast Pichia pastoris
- 23 October 2024
- Published by Springer Nature in Systems Microbiology and Biomanufacturing
- Vol. 5 (1) , 171-184
Overexpression and characterization of recombinant hCGβ-LTB vaccine in fed-batch culture of yeast Pichia pastoris
- 11 October 2024
- Published by Elsevier in Protein Expression and Purification
- Vol. 226, 106614
Expression, purification and characterization of a novel triple fusion protein developed for the immunotherapy of survivin positive cancers
- 11 October 2024
- Published by Elsevier in Protein Expression and Purification
- Vol. 226, 106614
Expression, purification and characterization of a novel triple fusion protein developed for the immunotherapy of survivin positive cancers
- 1 June 2017
- Published by Elsevier in Protein Expression and Purification
- Vol. 134, 132-138
Development of a novel recombinant LHRH fusion protein for therapy of androgen and estrogen dependent cancers
- 1 June 2017
- Published by Elsevier in Protein Expression and Purification
- Vol. 134, 132-138
Development of a novel recombinant LHRH fusion protein for therapy of androgen and estrogen dependent cancers
- 13 May 2015
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (8) , 1183-1190
Advances in development of a contraceptive vaccine against human chorionic gonadotropin
(2015). Advances in development of a contraceptive vaccine against human chorionic gonadotropin. Expert Opinion on Biological Therapy: Vol. 15, No. 8, pp. 1183-1190.
- 13 May 2015
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (8) , 1183-1190
Advances in development of a contraceptive vaccine against human chorionic gonadotropin
(2015). Advances in development of a contraceptive vaccine against human chorionic gonadotropin. Expert Opinion on Biological Therapy: Vol. 15, No. 8, pp. 1183-1190.
- 1 February 2015
- Published by Elsevier in Protein Expression and Purification
- Vol. 106, 10-17
Development of a recombinant hCG-specific single chain immunotoxin cytotoxic to hCG expressing cancer cells
- 1 February 2015
- Published by Elsevier in Protein Expression and Purification
- Vol. 106, 10-17
Development of a recombinant hCG-specific single chain immunotoxin cytotoxic to hCG expressing cancer cells